Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations

Journal of Chemotherapy

Volumn 20, Issue 3, 2008, Pages 327-335

  Turtinen, L W ^a   Croswell, A ^b   Obr, A ^b  

^a UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^b NONE

Author keywords

ABCD; ABLC; Amphotericin B; Antifungal agents; Microarray; THP 1 monocytes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AROMATASE; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN 9; LIPID; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRILYSIN; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; STROMELYSIN 2; TRANSCRIPTION FACTOR CDX1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WNT2 PROTEIN;

APOPTOSIS; ARTICLE; BIRC3 GENE; CONTROLLED STUDY; DRUG FORMULATION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; MICROARRAY ANALYSIS; MIG GENE; MONOCYTE; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 47349131787     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.3.327     Document Type: Article

References (32)

1. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27S: S12-S16.
2. Saliba F. Antifungals and renal safety-getting the balance right. Int J Antimicrob Agents 2006;27S: S21-S24.
3. Tiphine M, Letscher-Bru V, Herbrecht, R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transplant Infect Dis 1999; 1: 273-283.
4. Dupont B. Overview of the lipid formulations of Amphotericin B. J Antimicrob Chemother 2002;49: 31-36.
5. Alexander BD, Wingard J. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40: S414-421.
6. Walsh TJ, Hiemenz J, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26: 1383-1396.
7. Turtinen L, Prall D, Bremer L, Nauss R, Hartsel S. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob Agents Chemother 2004;48(2): 396-403.
8. Turtinen L, Bremer L, Prall D, Schwartzhoff J, Hartsel S. Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations. Immunopharmacol Immunotoxicol 2005;27(1): 85-93.
9. Rogers P, Jenkins J, Chapman S, Ndebele K, Chapman B, Cleary J. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998;178: 1726-1733.
10. Rogers P, Stiles J, Chapman S, Cleary J. Amphotericin B induces expression of genes encoding chemokines and adhesion molecules in the human monocytic cell line THP-1. J Infect Dis 2000;182: 1280-1283.
11. Cleary J, Rogers P, Chapman S. Differential transcription factor expression in human mononuclear cells in response to amphotericin B: Identification with complementary DNA microarray technology. Pharmacotherapy 2001;21(9): 1046-1054.
12. Simitsopoulou M, Roilides E, Dotis J et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005;49(4): 1397-1403.
13. Rogers P, Barker K, Herring V, Jacob M. Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell Line THP-1. J Antimicrob Chemother 2003;51: 405-408.
14. Rogers PD, Pearson, MM, Cleary JD, Sullivan DC, Chapman SW. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin b in human mononuclear cells identified by cDNA microarray analysis. J Antimicrob Chemother 2002;50(6): 811-817.
15. Sau K, Mambula S, Latz E, Henneki P, Golenbock D, Levitz S. The antifungal drug amphotericin B promotes inflammatory cytokine release by a toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003;278(39): 37561-37568.
16. Livak K, Schmittgeri T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C (T) method. Methods 2001;25(4): 402-408.
17. Hemmi H, Breitman T. Induction of functional differentiation of a human monocytic leukemia cell line (THP-1) by retinoic acid and cholera toxin. Jpn J Cancer Res 1985; 76: 345-351.
18. Krakauer T, Oppenheim. J. Interleukin 1 production by a human acute monocytic leukemia cell line. Cell Immunol 1983;80: 223-229.
19. Clayette P, Martin M, Beringue V et al. Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages. Antimicrob Agents Chemother 2000;44(2): 405-407.
20. Wolk K, Sabat R. Interleukin 22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17(5): 367-380.
21. Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while IL-9 induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine 2004;26(3): 122-130.
22. Amin MA, Mansfield P, Pakozdi A et al. Interleukin 18 induces angiogenic factors in rheumatoid arthritis synovia! tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007;56(6): 1787-1797.
23. Razonable R, Henault M, Lee L et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob Agents Chemother 2005;49(4): 1617-1621.
24. Matsou K, Hotokezaka H, Ohara, N et al. Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol Immunology 2006;50(4): 337-347.
25. Legrand P, Vertut.-D A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996;37: 519-533.
26. Bellocchio S, Ganziano R, Bozza S et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting toll-like receptor signaling from TLR-2 to TLR-4. J Antimicrob Chemother 2005;55(2): 214-222.
27. Lewis R, Chamilus G, Prince R et al. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007; 51(3):1078-1081.
28. Filion MC, Phillips NC. Anti-inflammatory activity of cationic lipids. Br J Pharmacol 1997; 122(3) :551-557.
29. Conte D, Holcik M, Lefebvre C et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Molecular Cell Biol 2006;26(2): 699-708.
30. Perera L, Waldmann T. Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc Natl Acad Sci USA 1998;95(24):14308-14313.
31. Lamkanfi M, Denecker G, Kalai M et al. INCA, a novel human caspase recruitment domain protein that inhibits inter-leukin-1 beta generation. J Biol Chem 2004;279(50): 51729-51738.
32. Conti P, Kempuraj D, Kandere K et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003;86: 123-129.